Next generation sequencing and reverse vaccinology approaches allow for vaccine development directly from pathogen genomic data. Reverse vaccinology was first used in the 1990s to develop a vaccine for Neisseria meningitidis B by sequencing its genome, predicting potential antigens, and testing them experimentally. The workflow involves sequencing pathogen genomes, predicting proteins and epitopes, filtering for antigenic proteins, predicting T-cell and B-cell epitopes, evaluating epitopes, predicting structures, and designing vaccine candidates for testing.
Related topics: